Radiation Oncology Clinical Research Seminar to be Held at the University of Florida

Publication
Article
OncologyONCOLOGY Vol 13 No 11
Volume 13
Issue 11

A three-day interdisciplinary cancer conference will be held March 2 through 4, 2000, at the Best Western Gateway Grand in Gainesville, Florida. The seminar will emphasize the latest advances in radiation therapy techniques and results. It will include refresher courses by senior faculty, panel discussions, and new departmental research results. Visiting Professor will be Professeur Jean-Pierre Gerard, Service de Radiotherapie-Oncologie, Hôpitaux de Lyon, France. Other presentations will be made by clinicians from the University of Florida Department of Radiation Oncology.

A three-day interdisciplinary cancer conference will be held March 2 through 4, 2000, at the Best Western Gateway Grand in Gainesville, Florida. The seminar will emphasize the latest advances in radiation therapy techniques and results. It will include refresher courses by senior faculty, panel discussions, and new departmental research results. Visiting Professor will be Professeur Jean-Pierre Gerard, Service de Radiotherapie-Oncologie, Hôpitaux de Lyon, France. Other presentations will be made by clinicians from the University of Florida Department of Radiation Oncology.

Concurrent meetings will be held for radiation therapy physicists on March 2 and 3, for radiation therapists on March 3 and 4, and for radiation oncology nurses on March 3 and 4. For further information, contact:
William M. Mendenhall, MD, 2000 Seminar Coordinator, Department of Radiation Oncology, University of Florida , Health Science Center, P. O. Box 100385, Gainesville, FL 100385, Phone: (352) 395-0287, Fax: (352) 395-0759, e-mail: mendewil@shands.ufl.edu

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content